Sustained, Long-Lasting Response From Cryopyrin-Associated Periodic Syndromes (CAPS)*
- Sustained, complete clinical improvement was demonstrated in patients receiving ILARIS® (canakinumab) versus placebo over the 24-week, double-blind withdrawal period of the clinical trial (3 doses)1,2
- A disease flare was defined as a CRP and/or SAA values >30 mg/L and either a score of mild or worse for disease activity or a score of minimal or worse for disease activity and skin disease1,2
Sustained Improvement in Inflammation Markers
- Serum amyloid A (SAA) and C-reactive protein (CRP) levels in patients receiving ILARIS® were normalized and sustained1,2
*The pivotal study included an 8-week, open-label period (Part 1) and a 24-week, randomized, double-blind, placebo-controlled withdrawal period (Part 2).1,2
†Using last observation carried forward (LOCF) in intent-to-treat (ITT) population.
![[Image: Novartis]s](/images/nova-btn-logo.jpg){kind=logo}